Cardlytics Inc

For the period ended Dec 31, 2023. Filed Mar 14, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 14, 2024

CDLX$1.82-6.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(Amounts in thousands, except per share amounts)

	Year Ended December 31,
	2023	2022	2021
Revenue	$309,204	$298,542	$267,116
Costs and expenses:
Partner Share and other third-party costs	150,578	155,507	141,273
Delivery costs	28,248	30,403	22,503
Sales and marketing expense	57,425	74,745	65,996
Research and development expense	51,352	54,435	38,104
General and administration expense	58,810	81,446	66,222
Acquisition, integration and divestiture (benefits) costs	(6,313)	(2,874)	24,372
Change in fair value of contingent consideration	1,246	(128,174)	1,374
Impairment of goodwill and intangible assets	70,518	453,288	—
Loss on divestiture	6,550	—	—
Depreciation and amortization expense	26,460	37,544	29,871
Total costs and expenses	444,874	756,320	389,715
Operating loss	(135,670)	(457,778)	(122,599)
Other income (expense):
Interest expense, net	(2,336)	(2,556)	(12,563)
Foreign currency gain (loss)	3,304	(6,376)	(1,267)
Total other income (expense)	968	(8,932)	(13,830)
Loss before income taxes	(134,702)	(466,710)	(136,429)
Income tax benefit	—	1,446	7,864
Net Loss	(134,702)	(465,264)	(128,565)
Net Loss attributable to common stockholders	$(134,702)	$(465,264)	$(128,565)
Net loss per share attributable to common stockholders, basic and diluted	$(3.69)	$(13.92)	$(3.99)
Weighted-average common shares outstanding, basic and diluted	36,488	33,419	32,202

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.